Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Telisotuzumab Vedotin for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
Toledo, Ohio
This trial will assess a new drug to treat non-small cell lung cancer (NSCLC). 70 participants will receive IV infusions every 2 weeks to see how the treatment affects their disease.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.